A patient was diagnosed with autoimmune thrombocytopenia and concurrent diffuse large B-cell lymphoma (DLBCL). Both autoimmune thrombocytopenia and DLBCL were successfully treated using chemotherapy, while steroid therapy, rituximab monotherapy, and high-dose parenteral glucocorticoid therapy combined with high-dose intravenous immunoglobulin failed to improve thrombocytopenia. A greater understanding of the pathogenesis and treatment options can only be definitively clarified by analyses of settings such as the present case, as autoimmune thrombocytopenia is uncommon in patients with malignant lymphoma and the etiology and optimal treatment remain unclear.
Introduction
Non-hematological autoimmune disorders are occasionally associated with malignant lymphoma (ML), but autoimmune thrombocytopenia is rare in patients with ML, occurring in only 0-1.8% of patients with ML (1) . Autoimmune thrombocytopenia in the setting of ML thus has not been discussed in terms of etiology or treatment in detail, while autoimmune thrombocytopenia in the setting of ML is potentially life-threatening and difficult to treat.
We describe herein an interesting case of a patient with autoimmune thrombocytopenia concurrent with diffuse large B-cell lymphoma (DLBCL), in whom both autoimmune thrombocytopenia and DLBCL were successfully treated using chemotherapy. To the best of our knowledge, to date only 9 patients with DLBCL associated with autoimmune thrombocytopenia have been reported in the literature (2-10).
Case Report
A 59-year-old woman was referred to our hospital and admitted for further evaluation of an abdominal mass in June 2009. She had been suffering from rheumatoid arthritis (RA) for 6 months before admission, and was being treated with steroids, but had experienced constant pain in the joints of both hands and wrists associated with morning stiffness without improvement of serum rheumatoid factor. The platelet count was normal (28.4×10 4 /μL) in February 2009. Two months before admission, the patient noted the onset of epigastralgia with no change in clinical symptoms of RA, at which time the platelet count was 10.6×10 4 /μL. The patient had taken loxoprofen sodium to relieve symptoms from 2 weeks prior to admission. On admission, a weight loss of 3 kg during the previous 2 months was noted with a body temperature of 35.6 , a regular heart rate of 90 beats/min and blood pressure of 126/70 mmHg. No petechial purpura over the skin or mucosal hemorrhage was seen. Superficial lymph nodes were not palpable. The abdomen was enlarged and filled with a huge mass, but the liver and spleen were not palpable. Bowel sounds were decreased.
Laboratory findings (Table 1 ) revealed a low platelet count (4.5×10 4 /μL), elevated serum lactate dehydrogenase (LDH) levels (352 IU/L) and C-reactive protein (CRP) levels (4.83 mg/dL). Disseminated intravascular coagulation was excluded based on levels of fibrinogen, fibrin degradation products and the cross-linked fragment, D-dimer. The Increased uptake in multiple lymph node regions inferior to the diaphragm involving part of the ascending colon, and a left supraclavicular lymph node, not spleen, was evident on positron emission tomography/computed tomography ( Fig. 1) . Ultrasonographic examination of the abdomen demonstrated a hypoechoic mass in both the pancreas and right adrenal gland, suggesting the involvement of lymphoma. The spleen was normal in size. The presence of ascitic fluid in Morison and Douglas pouch was also noted. Colonoscopy revealed several submucous tumors with partial ulceration in the ascending colon. Histological features of the biopsy specimen in colonic lesions indicated largesized atypical lymphoid cells proliferating invasively into the mucosal lamina propria. Atypical lymphoid cells were positive for CD20 and CD79a, but negative for CD3 and CD45RO. In addition, 60-70% of cells were positive for MIB-1 staining. DLBCL (clinical stage IV) complicated with autoimmune thrombocytopenia was thus diagnosed. Drug-induced thrombocytopenia associated with loxoprofen sodium was considered unlikely, as the platelet count had not been increased for more than a month since stopping this drug and platelet transfusions at colonoscopy showed little effect. The clinical course is shown in Fig. 2 . We did not perform Helicobacter pylori (HP) eradication therapy, as serum HP antibody, urea breath test and endoscopic biopsy did not demonstrate the presence of HP. The patient was started on prednisolone (PSL) at 50 mg/day. Rituximab monotherapy was also started weekly from day 8. However, platelet count gradually fell to <0.5×10 4 /μL. Pulsed doses of methylprednisolone (mPSL) (1,000 mg/day for 3 days) were started on day 15, as 2-week PSL did not seem to increase the effect. PSL at a dose of 50 mg was re-started after the administration of pulsed doses of mPSL. The patient also received 0.5 g/kg/day of intravenous immunoglobulin (IVIg) for 5 days from day 23 to accelerate increases in platelet count. On day 29, the patient was finally treated with a half dose of rituximab-cyclophosphamide-doxorubicine-vincristineprednisolone (R-CHOP) therapy, as the platelet count remained at <0.5×10 4 /μL and the patient experienced generalized purpura on the extremities and trunk, along with mucosal hemorrhage. We performed half-dose R-CHOP therapy, because reliable evidence on the recovery of platelet count with chemotherapy is lacking. Seven days after R-CHOP therapy, the platelet count started to increase and it was normalized by 2 weeks after the start of R-CHOP therapy. Complete remission was achieved after the third cycle and the platelet count has remained within normal limits.
Discussion
The present patient was diagnosed with autoimmune thrombocytopenia and concurrent DLBCL. Autoimmune thrombocytopenia is less common in patients with ML, affecting 0% to 1.8% of cases (1). Among these, autoimmune thrombocytopenia with DLBCL is considered quite rare and only 9 cases have been reported to date (2-10).
Although autoimmune thrombocytopenia, which occurs at or after the diagnosis of ML, has been reported to show a poor response to treatment (1), both autoimmune thrombocytopenia and DLBCL in the present case were successfully treated using R-CHOP therapy, while steroid therapy, rituximab monotherapy, and high-dose parenteral glucocorticoid therapy combined with high-dose IVIg, which is generally considered an appropriate first-line therapy for immune thrombocytopenia in emergency situations, showed no effect on thrombocytopenia. Conversely, rituximab, a chimeric murine/human monoclonal antibody directed against the CD20 antigen expressing pre-B and mature B cells, offers a promising option for the treatment of refractory cases of immune thrombocytopenia, due to its excellent tolerability and minimal side effects. There are early and late responders to rituximab therapy, so a conclusive statement as to whether two administrations of rituximab had any effect on autoimmune thrombocytopenia is not yet possible. Moreover, a limited number of cases have been reported, particularly among patients with autoimmune thrombocytopenia in the setting of ML. More cases are needed to assess the potential utility of rituximab.
This patient showed marked improvements in platelet count after chemotherapy. This is the first case describing the usefulness of R-CHOP therapy in this situation. The platelet count was inversely correlated with the LDH level, thus decreasing the tumor burden seemed to lead to recovery in the platelet count. In fact, more than half of the patients with autoimmune thrombocytopenia and ML achieved a CR after operation or chemotherapy for ML (1) . Platelet count also showed an inverse correlation with the level of plateletassociated IgG (PA-IgG), suggesting that the immune destruction due to elevated levels of PA-IgG could be the cause of thrombocytopenia, and ML itself might be associated with the production of PAIgG. Although the exact etiology of the association between autoimmune thrombocytopenia and ML has not yet been established, some immune response of the host to the underlying ML itself may play an important role in the pathogenesis of immune thrombocytopenia.
Interestingly, clinical symptoms associated with RA, such as constant pain in the joints of both hands and wrists associated with morning stiffness, disappeared and rheumatoid factor was decreased during the clinical course. While nonhematologic autoimmune diseases are common and often precede the diagnosis of lymphoma, this appears to represent the first report of DLBCL accompanying autoimmune thrombocytopenia and RA.
In conclusion, the study described an interesting case of a woman who developed autoimmune thrombocytopenia concurrent with DLBCL. As this setting is uncommon, analysis of such cases is critical for a greater understanding of the pathogenesis and the best treatment options.
The authors state that they have no Conflict of Interest (COI).
